Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies
Defective apoptosis signaling is a typical feature of classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma. In these malignancies, the transcription factor nuclear factor-kappaB (NF-kappaB) is a critical mediator of apoptosis resistance and oncog...
Saved in:
Published in | Clinical cancer research Vol. 11; no. 22; pp. 8186 - 8194 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
15.11.2005
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Defective apoptosis signaling is a typical feature of classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma. In these malignancies, the transcription factor nuclear factor-kappaB (NF-kappaB) is a critical mediator of apoptosis resistance and oncogenic growth, making it an attractive therapeutic target. Here, we sought to determine how to overcome apoptosis resistance experimentally in these malignancies by targeting NF-kappaB.
We investigated the effect of different inhibitors of NF-kappaB on classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma cell lines harboring different molecular defects in apoptosis signaling both quantitatively and qualitatively.
The cyclopentenone prostaglandin, 15-deoxy-Delta12,14-prostaglandin J(2), a known inhibitor of NF-kappaB, induced caspase-dependent apoptosis; it restored mitochondrial apoptotic signaling by down-regulation of X-linked inhibitor of apoptosis protein and heat shock protein 27 and led to breakdown of the mitochondrial membrane potential and, finally, cleavage of caspase-3 irrespective of IkappaBalpha mutational status. Surprisingly, 15-deoxy-Delta12,14-prostaglandin J(2) and the IkappaB kinase inhibitor curcumin both reduced nuclear levels of p65 in cell lines lacking IkappaBalpha, suggesting that inhibition of nuclear translocation of NF-kappaB can occur in the absence of IkappaBalpha. Finally, a synthetic peptide that specifically abrogates the assembly of the IkappaB kinase complex killed IkappaBalpha-defective cells by induction of apoptosis, paralleled by reduction of nuclear NF-kappaB.
These results show that molecular defects in apoptotic signaling, such as IkappaBalpha mutations, can be circumvented by targeting NF-kappaB through inhibition of the IkappaB kinase complex followed by induction of apoptosis in classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma. Thus, targeting IkappaB kinases may represent an attractive therapeutic approach against these malignancies regardless of the mutational status of IkappaBalpha. |
---|---|
AbstractList | Defective apoptosis signaling is a typical feature of classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma. In these malignancies, the transcription factor nuclear factor-kappaB (NF-kappaB) is a critical mediator of apoptosis resistance and oncogenic growth, making it an attractive therapeutic target. Here, we sought to determine how to overcome apoptosis resistance experimentally in these malignancies by targeting NF-kappaB.
We investigated the effect of different inhibitors of NF-kappaB on classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma cell lines harboring different molecular defects in apoptosis signaling both quantitatively and qualitatively.
The cyclopentenone prostaglandin, 15-deoxy-Delta12,14-prostaglandin J(2), a known inhibitor of NF-kappaB, induced caspase-dependent apoptosis; it restored mitochondrial apoptotic signaling by down-regulation of X-linked inhibitor of apoptosis protein and heat shock protein 27 and led to breakdown of the mitochondrial membrane potential and, finally, cleavage of caspase-3 irrespective of IkappaBalpha mutational status. Surprisingly, 15-deoxy-Delta12,14-prostaglandin J(2) and the IkappaB kinase inhibitor curcumin both reduced nuclear levels of p65 in cell lines lacking IkappaBalpha, suggesting that inhibition of nuclear translocation of NF-kappaB can occur in the absence of IkappaBalpha. Finally, a synthetic peptide that specifically abrogates the assembly of the IkappaB kinase complex killed IkappaBalpha-defective cells by induction of apoptosis, paralleled by reduction of nuclear NF-kappaB.
These results show that molecular defects in apoptotic signaling, such as IkappaBalpha mutations, can be circumvented by targeting NF-kappaB through inhibition of the IkappaB kinase complex followed by induction of apoptosis in classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma. Thus, targeting IkappaB kinases may represent an attractive therapeutic approach against these malignancies regardless of the mutational status of IkappaBalpha. PURPOSEDefective apoptosis signaling is a typical feature of classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma. In these malignancies, the transcription factor nuclear factor-kappaB (NF-kappaB) is a critical mediator of apoptosis resistance and oncogenic growth, making it an attractive therapeutic target. Here, we sought to determine how to overcome apoptosis resistance experimentally in these malignancies by targeting NF-kappaB.EXPERIMENTAL DESIGNWe investigated the effect of different inhibitors of NF-kappaB on classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma cell lines harboring different molecular defects in apoptosis signaling both quantitatively and qualitatively.RESULTSThe cyclopentenone prostaglandin, 15-deoxy-Delta12,14-prostaglandin J(2), a known inhibitor of NF-kappaB, induced caspase-dependent apoptosis; it restored mitochondrial apoptotic signaling by down-regulation of X-linked inhibitor of apoptosis protein and heat shock protein 27 and led to breakdown of the mitochondrial membrane potential and, finally, cleavage of caspase-3 irrespective of IkappaBalpha mutational status. Surprisingly, 15-deoxy-Delta12,14-prostaglandin J(2) and the IkappaB kinase inhibitor curcumin both reduced nuclear levels of p65 in cell lines lacking IkappaBalpha, suggesting that inhibition of nuclear translocation of NF-kappaB can occur in the absence of IkappaBalpha. Finally, a synthetic peptide that specifically abrogates the assembly of the IkappaB kinase complex killed IkappaBalpha-defective cells by induction of apoptosis, paralleled by reduction of nuclear NF-kappaB.CONCLUSIONSThese results show that molecular defects in apoptotic signaling, such as IkappaBalpha mutations, can be circumvented by targeting NF-kappaB through inhibition of the IkappaB kinase complex followed by induction of apoptosis in classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma. Thus, targeting IkappaB kinases may represent an attractive therapeutic approach against these malignancies regardless of the mutational status of IkappaBalpha. |
Author | Thomas, Roman K Mani, Ozlem Berenbrinker, Daniel Schultze, Joachim L Wolf, Jürgen Sos, Martin L Smola-Hess, Sigrun Zander, Thomas Popov, Alexey |
Author_xml | – sequence: 1 givenname: Roman K surname: Thomas fullname: Thomas, Roman K organization: Molecular Tumor Biology and Tumor Immunology, Department I for Internal Medicine, Center for Molecular Medicine Cologne, University of Cologne, Germany – sequence: 2 givenname: Martin L surname: Sos fullname: Sos, Martin L – sequence: 3 givenname: Thomas surname: Zander fullname: Zander, Thomas – sequence: 4 givenname: Ozlem surname: Mani fullname: Mani, Ozlem – sequence: 5 givenname: Alexey surname: Popov fullname: Popov, Alexey – sequence: 6 givenname: Daniel surname: Berenbrinker fullname: Berenbrinker, Daniel – sequence: 7 givenname: Sigrun surname: Smola-Hess fullname: Smola-Hess, Sigrun – sequence: 8 givenname: Joachim L surname: Schultze fullname: Schultze, Joachim L – sequence: 9 givenname: Jürgen surname: Wolf fullname: Wolf, Jürgen |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16299251$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkMtuwyAQRVmkah7tL1SsurNkMGB72UR9RIrUTfYWxkNCg4EaXKnf1p-ro6Sbrkaae-ZoZpZo5ryDGVqQvKyynBV0jpYxfuQ5YSRnt2hOBK1ryskC_Wzd0bQmGe-w19iNyoIccBqki9Yr-T_QUiU_ZCcZglzjDmIwCbCV6nSm9OjUeUJavL0g0oajxGHwCcwk-oJB-R4i7kebTLAwKTSoFPGUyuBD8tFEHM1hchh3OLePYy8dXmcKrMX91J4ypwzEO3SjpY1wf60rtH953m_est3763bztMsCZySjVBMKwIWAohO5oEzzqixYxZhWZa1FXueKQtV2hWp5S9u6kowWnBctA9WVxQo9XrTTFZ8jxNT0Jp6XkQ78GBtRVYQJTibw4QqObQ9dEwbTy-G7-ft28Qt4o4FV |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 8194 |
ExternalDocumentID | 16299251 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .55 .GJ 18M 29B 2FS 2WC 34G 39C 3O- 476 53G 5GY 5RE 5VS 6J9 ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW AENEX AFFNX AFHIN AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 H~9 IH2 KQ8 L7B LSO MVM NPM OHT OK1 P0W P2P QTD RCR RHF RHI RNS SJN TR2 UDS VH1 W2D W8F WHG WOQ X7M XJT YKV ZCG ZGI 7X8 AETEA |
ID | FETCH-LOGICAL-p541-22f12ee566e3d60624f58734844fc79f6090c2e8bd3cb5b2b98a423553b4ecd73 |
ISSN | 1078-0432 |
IngestDate | Fri Aug 16 21:16:32 EDT 2024 Sat Sep 28 07:50:20 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 22 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p541-22f12ee566e3d60624f58734844fc79f6090c2e8bd3cb5b2b98a423553b4ecd73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 16299251 |
PQID | 68814651 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_68814651 pubmed_primary_16299251 |
PublicationCentury | 2000 |
PublicationDate | 2005-Nov-15 20051115 |
PublicationDateYYYYMMDD | 2005-11-15 |
PublicationDate_xml | – month: 11 year: 2005 text: 2005-Nov-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2005 |
SSID | ssj0014104 |
Score | 1.835761 |
Snippet | Defective apoptosis signaling is a typical feature of classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell lymphoma. In... PURPOSEDefective apoptosis signaling is a typical feature of classic Hodgkin's lymphoma, multiple myeloma, and activated B-cell-like diffuse large B-cell... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 8186 |
SubjectTerms | Active Transport, Cell Nucleus - drug effects Apoptosis - drug effects Apoptosis - physiology B-Lymphocytes - drug effects B-Lymphocytes - metabolism B-Lymphocytes - pathology Cell Line, Tumor Cell Nucleus - drug effects Cell Nucleus - metabolism Cell Survival - drug effects Chromans - pharmacology Dose-Response Relationship, Drug Heat-Shock Proteins - metabolism HSP27 Heat-Shock Proteins Humans I-kappa B Kinase - metabolism I-kappa B Proteins - genetics I-kappa B Proteins - metabolism Mutation Neoplasm Proteins - metabolism NF-kappa B - antagonists & inhibitors NF-kappa B - metabolism NF-KappaB Inhibitor alpha Prostaglandin D2 - analogs & derivatives Prostaglandin D2 - pharmacology Signal Transduction - drug effects Thiazolidinediones - pharmacology X-Linked Inhibitor of Apoptosis Protein - metabolism |
Title | Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies |
URI | https://www.ncbi.nlm.nih.gov/pubmed/16299251 https://search.proquest.com/docview/68814651 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9QwEICtbQ-IC4LyKtDiA7coKHbsbHKkpVUXVLgsUsVlZScOrNom0W720v_Br-HPMWM7j61aCbhEK4_Xyu588mM8D0LeCRAwoeKwZKYMhdRZqOCgEeaZ5pGB9WNqy72df0nOvolPF_JiMvk18lratPp9fnNnXMn_aBXaQK8YJfsPmu0HhQb4DPqFJ2gYnn-l41n1c6mX3Z6vwtTEaoVVH6o1rlG3Ba62TnipmkYdBQVesrcmQAse9sIVzhsGZ66LjcMNbCaHJQwEfw_8CLMenBAL45xBQKqaumlrzG6CHiHqyofKuBKARyHeDwTX0PzDlQNejzfFx110Zo4IrgKfgKg3VDsnJucHjsMNllnnI-hSIQS9Gfu7jdi55f5kre62flXw9ebKG6w7c4fEuD8X8Oln6AhTAot4ewpnI1RdnLOfkDFh33ilAAU21xYHlsBKzH222-2U251oh-zEDP1EP84-91dTgtmalP17YNpZ3__-U4rdrcwfk0f-mEE_OGaekImp9siDc-9I8ZT8HtChdUk9IXQLnbFgCx3q0aGIDvYa0KFjdKhHh_bo0A4d6tGhIO3RoT062GzRoQ4dOkbnGZmfnsyPz0JfxyNspGAh5yXjxsC5wcQFnJe5KGWKSZWEKPNpViZRFuXcpLqIcy0111mqYJMvZayFyYtp_JzsVnVlXhIqS5UUmsW5SJSI8CtMxzpTiieF0Xm6T952CljANIkvqCpTb9aLJEVbt2T75IXTy6Jx2VwWnfJe3St5TR4OJL4hu-1qYw5gK9rqQ4vGH0ocmJI |
link.rule.ids | 315,786,790 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibition+of+nuclear+translocation+of+nuclear+factor-kappaB+despite+lack+of+functional+IkappaBalpha+protein+overcomes+multiple+defects+in+apoptosis+signaling+in+human+B-cell+malignancies&rft.jtitle=Clinical+cancer+research&rft.au=Thomas%2C+Roman+K&rft.au=Sos%2C+Martin+L&rft.au=Zander%2C+Thomas&rft.au=Mani%2C+Ozlem&rft.date=2005-11-15&rft.issn=1078-0432&rft.volume=11&rft.issue=22&rft.spage=8186&rft_id=info%3Apmid%2F16299251&rft.externalDocID=16299251 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |